Deutsche Bank AG Has $428.16 Million Holdings in McKesson Co. (NYSE:MCK)

Deutsche Bank AG lifted its position in McKesson Co. (NYSE:MCK - Free Report) by 64.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 751,283 shares of the company's stock after acquiring an additional 293,148 shares during the period. Deutsche Bank AG owned approximately 0.59% of McKesson worth $428,164,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of McKesson by 212.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 42,339 shares of the company's stock valued at $24,129,000 after purchasing an additional 28,777 shares during the last quarter. EP Wealth Advisors LLC raised its holdings in shares of McKesson by 7.7% in the fourth quarter. EP Wealth Advisors LLC now owns 26,125 shares of the company's stock valued at $14,889,000 after purchasing an additional 1,867 shares during the last quarter. Colonial Trust Co SC raised its holdings in shares of McKesson by 30.3% in the fourth quarter. Colonial Trust Co SC now owns 447 shares of the company's stock valued at $255,000 after purchasing an additional 104 shares during the last quarter. BOKF NA raised its holdings in shares of McKesson by 5.8% in the fourth quarter. BOKF NA now owns 1,147 shares of the company's stock valued at $667,000 after purchasing an additional 63 shares during the last quarter. Finally, Brevan Howard Capital Management LP raised its holdings in shares of McKesson by 30.1% in the fourth quarter. Brevan Howard Capital Management LP now owns 10,524 shares of the company's stock valued at $5,998,000 after purchasing an additional 2,434 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at McKesson

In other news, CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $600.66, for a total value of $5,382,514.26. Following the completion of the transaction, the chief executive officer now owns 69,625 shares of the company's stock, valued at approximately $41,820,952.50. This represents a 11.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Leann B. Smith sold 188 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the transaction, the executive vice president now directly owns 1,051 shares of the company's stock, valued at $640,679.09. This trade represents a 15.17% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,110 shares of company stock worth $10,855,706. Company insiders own 0.11% of the company's stock.

McKesson Trading Up 0.6%

Shares of NYSE:MCK traded up $3.87 on Friday, hitting $694.12. The company had a trading volume of 2,028,420 shares, compared to its average volume of 899,241. McKesson Co. has a 1-year low of $464.42 and a 1-year high of $728.48. The stock has a market cap of $86.99 billion, a price-to-earnings ratio of 31.78, a P/E/G ratio of 1.29 and a beta of 0.53. The stock has a 50 day moving average price of $678.24 and a 200 day moving average price of $621.72.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $10.12 EPS for the quarter, beating the consensus estimate of $9.83 by $0.29. McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. The firm had revenue of $90.82 billion for the quarter, compared to the consensus estimate of $94 billion. During the same period in the previous year, the company earned $6.18 earnings per share. The company's quarterly revenue was up 18.9% on a year-over-year basis. Sell-side analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Stockholders of record on Monday, June 2nd will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, June 2nd. This represents a $2.84 annualized dividend and a dividend yield of 0.41%. McKesson's dividend payout ratio is presently 13.00%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MCK. StockNews.com downgraded shares of McKesson from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Mizuho raised their target price on shares of McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a research note on Thursday, April 3rd. Bank of America raised their target price on shares of McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a research note on Friday. Wells Fargo & Company raised their target price on shares of McKesson from $641.00 to $691.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, Evercore ISI lifted their price target on McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, McKesson has an average rating of "Moderate Buy" and an average price target of $686.69.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.